Does empagliflozin pretreatment prevent severe lethal ventricular arrhythmia in a preclinical model of myocardial ischemia and reperfusion injury?
Empagliflozin may offer cardioprotective benefits against ischemia/reperfusion-induced sudden cardiac death through ERK1/2 pathway activation.
Pretreatment with empagliflozin protects the heart from subsequent severe lethal ventricular arrhythmia induced by myocardial ischemia and reperfusion injury. These protective benefits may occur as a consequence of activation of the ERK1/2-dependent cell-survival signaling pathway in a glucose-independent manner.
Hu et al. (Mon,) studied this question.